Author: Osuchowski, Marcin F; Winkler, Martin S; Skirecki, Tomasz; Cajander, Sara; Shankar-Hari, Manu; Lachmann, Gunnar; Monneret, Guillaume; Venet, Fabienne; Bauer, Michael; Brunkhorst, Frank M; Weis, Sebastian; Garcia-Salido, Alberto; Kox, Matthijs; Cavaillon, Jean-Marc; Uhle, Florian; Weigand, Markus A; Flohé, Stefanie B; Wiersinga, W Joost; Almansa, Raquel; de la Fuente, Amanda; Martin-Loeches, Ignacio; Meisel, Christian; Spinetti, Thibaud; Schefold, Joerg C; Cilloniz, Catia; Torres, Antoni; Giamarellos-Bourboulis, Evangelos J; Ferrer, Ricard; Girardis, Massimo; Cossarizza, Andrea; Netea, Mihai G; van der Poll, Tom; Bermejo-MartÃn, Jesús F; Rubio, Ignacio
Title: The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity Cord-id: fkqk70ts Document date: 2021_5_6
ID: fkqk70ts
Snippet: The zoonotic SARS-CoV-2 virus that causes COVID-19 continues to spread worldwide, with devastating consequences. While the medical community has gained insight into the epidemiology of COVID-19, important questions remain about the clinical complexities and underlying mechanisms of disease phenotypes. Severe COVID-19 most commonly involves respiratory manifestations, although other systems are also affected, and acute disease is often followed by protracted complications. Such complex manifestat
Document: The zoonotic SARS-CoV-2 virus that causes COVID-19 continues to spread worldwide, with devastating consequences. While the medical community has gained insight into the epidemiology of COVID-19, important questions remain about the clinical complexities and underlying mechanisms of disease phenotypes. Severe COVID-19 most commonly involves respiratory manifestations, although other systems are also affected, and acute disease is often followed by protracted complications. Such complex manifestations suggest that SARS-CoV-2 dysregulates the host response, triggering wide-ranging immuno-inflammatory, thrombotic, and parenchymal derangements. We review the intricacies of COVID-19 pathophysiology, its various phenotypes, and the anti-SARS-CoV-2 host response at the humoral and cellular levels. Some similarities exist between COVID-19 and respiratory failure of other origins, but evidence for many distinctive mechanistic features indicates that COVID-19 constitutes a new disease entity, with emerging data suggesting involvement of an endotheliopathy-centred pathophysiology. Further research, combining basic and clinical studies, is needed to advance understanding of pathophysiological mechanisms and to characterise immuno-inflammatory derangements across the range of phenotypes to enable optimum care for patients with COVID-19.
Search related documents:
Co phrase search for related documents- ace angiotensin and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- ace angiotensin ii and activation peptide: 1
- ace angiotensin ii and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- ace inhibitor and activation peptide: 1
- ace inhibitor and active replication: 1
- ace inhibitor and acute ards respiratory distress syndrome: 1, 2, 3, 4
- ace inhibitor and acute condition: 1
- ace inhibitor enzyme and acute ards respiratory distress syndrome: 1, 2, 3, 4
- activation signature and acute ards respiratory distress syndrome: 1, 2
- active replication and acute ards respiratory distress syndrome: 1, 2
Co phrase search for related documents, hyperlinks ordered by date